As of March 2020, the mainstream ECMO brands in the domestic market are mainly Medtronic, Midos, Mykovi and Sorin from Europe and the United States. According to data from the Chinese Physicians Association's Professional Committee on Extracorporeal Life Support, as of the end of 2018, there were more than 400 ECMO devices in China***, with the products of two companies, Mykovi and Sorin, accounting for the lion's share of the domestic market.
The top three global suppliers in the ECMO Chinese market: Germany's Mykovi belongs to Sweden's GetingeGroup, accounting for more than 70 percent of the Chinese market;
followed by Medtronic, which accounts for 10 percent; and Sorin, which belongs to the U.K.-based LivaNova, with 10 percent of the market. 10%. Other manufacturers include Terumo, Medos (belonging to Fresenius) and others.
Chinese companies are poised to start making inroads into a generally favorable market, but so far there are no real finished ECMO products from China.
Extended information:
Beginning with the invention of an artificial heart-lung machine by Dr. Gibbon in 1953, the first time that extracorporeal circulation was used in a clinical heart surgery was a success. This made it possible to use artificial heart-lung machine systems for prolonged cardiopulmonary assistance. Extracorporeal membrane pulmonary oxygenation (ECMO) is actually an extended and prolonged application of cardiopulmonary bypass, which has been used to treat life-threatening respiratory failure for more than 20 years.
Membrane oxygenators appeared from 1960 to 1970, and anticoagulation control technology was perfected from 1965 to 1975, which made the extended use of cardiopulmonary bypass possible. Membrane oxygenators separate the blood and gas phases with a semipermeable membrane, which protects the red blood cells and platelets, and makes it possible to perform ECMO safely for a longer period of time.
In 1971, Dr. Hill used ECMO for the first time to treat a 24-year-old male patient with progressive aggravation of respiratory failure due to multiple trauma, and after 75 hours of ECMO treatment, the patient was out of danger and resuscitated successfully. So some hospitals carried out ECMO one after another, but it soon came to an end due to the low success rate.
In 1975, Dr. Bartlett successfully treated a neonate with persistent fetal circulation with ECMO for the first time. Subsequent experience with ECMO techniques in neonatal applications increased rapidly, and ECMO is now considered the standard treatment for severe respiratory failure in neonates and infants.
A 1993 survey by Zwushenberrger et al. of 5,000 ECMO-treated children with respiratory failure showed a survival rate of 82%, compared with an 80% mortality rate with conventional treatment. This in turn stimulated research enthusiasm, and in 1994 made a stage of conclusion: ECMO for newborns is better than adults, respiratory failure is better than cardiac failure efficacy.
With the continuous development of medical technology, material technology, and mechanical technology, the support time of ECMO has been prolonged, and the efficacy of ECMO in adults has been improved, which has been more widely used in clinical critical care. Even some medical centers have designated ECMO devices as the basic configuration of ambulances, so that ECMO goes to the pre-hospital and better performs the function of emergency.
Reference:
People's Daily Online - All rely on imported "life-saving device" ECMO localization difficult where?